An Adaptive Phase I/II Study to Assess Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Crovalimab in Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Latest Information Update: 23 May 2024
At a glance
- Drugs Crovalimab (Primary) ; Crovalimab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Acronyms COMPOSER
- Sponsors Chugai Pharmaceutical; Roche
- 20 May 2024 Planned End Date changed from 10 Jun 2031 to 31 Jan 2026.
- 20 May 2024 Planned primary completion date changed from 31 Mar 2031 to 31 Jan 2026.
- 01 Aug 2023 Results assessing long-term outcomes crovalimab in patients with paroxysmal nocturnal haemoglobinuria, published in the European Journal of Haematology.